Printer Friendly

Active Biotech reports on initial results in ARPEGGIO Phase II trial.

M2 EQUITYBITES-December 4, 2017-Active Biotech reports on initial results in ARPEGGIO Phase II trial

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Active Biotech AB (STO:ACTI), a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer, announced on Friday initial results from the Phase II proof of concept study of laquinimod in Primary Progressive MS (PPMS) sponsored by Active Biotech's partner Teva Pharmaceuticals Industries Ltd.

Reportedly, the primary endpoint of brain atrophy as defined by percent brain volume change (PBVC) from baseline to week 48, was not met after daily oral doses with 0.6 mg laquinimod.

Also, the secondary endpoint of time to confirmed disability progression was also not met. There was, however, a reduction in new T2 lesions observed in patients treated with laquinimod 0.6 mg.

According to the company, the clinical safety profile of laquinimod 0.6 mg daily in PPMS patients resembled the safety profile demonstrated in relapsing remitting MS patients. The most common adverse events reported by patients treated with laquinimod 0.6 mg daily were nasopharyngities, headache, upper respiratory tract infection and back pain.

The ARPEGGIO study is a multinational, multicentre, randomised, double-blind, parallel-group, placebo-controlled, Phase II trial evaluating the efficacy, safety and tolerability of laquinimod at 0.6 and 1.5 mg/day in patients with PPMS. The higher-dose (1.5 mg) arm of the trial was discontinued in January 2016.

This study has the primary endpoint of brain atrophy as defined by PBVC from baseline to week 48, assessed by magnetic resonance imaging (MRI) analysis. Secondary endpoints include time to confirmed disability progression, the number of new T2 lesions and extended MRI data.

Data from the trial will be presented at a future scientific conference and the full results will be published, the company added.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Dec 4, 2017
Words:307
Previous Article:InfraREIT declares dividend of USD0.25 per share for quarter.
Next Article:Catena announces acquisition of three properties in Gothenburg.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters